Abstract
Background Several studies have focused on the prognostic role of microRNA 222 in glioma. But different conclusions were drawn by these studies. We aimed to systematically evaluate the role of microRNA 222 in glioma by conducting a meta-analysis. Methods A systematic literature search until January 2020 was conducted in Web of Science, EMBASE, Cochrane Library, PubMed, and China National Knowledge Infrastructure. The general characteristics and relevant data of nine articles were extracted. Hazard ratios (HRs) with 95% confidence intervals (CIs) were applied to evaluate the prognostic role of microRNA 222 in glioma. The primary outcomes were overall survival (OS) and disease-free survival (DFS). Results Nine articles (11 data sets) with 1564 patients were included. We systematically evaluated the role of microRNA 222 for OS and DFS in glioma patients (HR for OS = 1.72; 95% CI, 1.31-2.26; p = 0.001; HR for DFS = 1.02; 95% CI, 0.86-1.22; p = 0.032). Subgroup analyses were performed according to the sources of patients, the types of the samples, the stages of the tumors, the methods for detecting the microRNA 222, and the sample size. No significant publication bias was found. Conclusion In conclusion, our study provided evidence that a high expression of microRNA 222 was related to worse overall survival in glioma patients. However, given the limited study number, more high-quality studies are warranted in the future.
Highlights
Glioma is the most common cancer in the central nervous system with high mortality and recurrence [1]
Different conclusions were drawn by these studies
7 data sets were related to overall survival (OS) and 4 data sets were related to the diseasefree survival (DFS)
Summary
Glioma is the most common cancer in the central nervous system with high mortality and recurrence [1]. Many studies focused on microRNAs. For example, microRNA 373, 15, 107, 133, and 211 were reported to be related to the prognosis of glioma [13,14,15,16,17]. Several studies have focused on the prognostic role of microRNA 222 in glioma. We aimed to systematically evaluate the role of microRNA 222 in glioma by conducting a meta-analysis. We systematically evaluated the role of microRNA 222 for OS and DFS in glioma patients (HR for OS = 1:72; 95% CI, 1.31-2.26; p = 0:001; HR for DFS = 1:02; 95% CI, 0.86-1.22; p = 0:032). Our study provided evidence that a high expression of microRNA 222 was related to worse overall survival in glioma patients. Given the limited study number, more high-quality studies are warranted in the future
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
